Fate Therapeutics

Yahoo Finance • 5 months ago

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Are you a successful asset manager who has already amassed more than $1 billion in personal wealth? If not, there are probably a few things you can learn from the small list of folks who have. Luckily for us everyday investors, the Securi... Full story

Yahoo Finance • 7 months ago

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welco... Full story

Yahoo Finance • 10 months ago

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a good week for Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders, because the company has just released its latest yearly results, and the shares gained 4.5% to US$7.14. The results look positive overall; while revenues of US$6... Full story

Yahoo Finance • 10 months ago

Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results

Revenue: Reported $1.7 million for the fourth quarter of 2023. Operating Expenses: GAAP operating expenses were $49.8 million for the fourth quarter. Net Loss: Recorded a net loss of $44.1 million for the fourth quarter. Cash Position: End... Full story

Yahoo Finance • last year

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared b... Full story

Yahoo Finance • last year

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockho... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Ardelyx, Inc., Leslie’s, Inc., Enovix Corporation, and Fate Therapeutics, Inc. If you a... Full story

Yahoo Finance • last year

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... Full story

Yahoo Finance • last year

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), National Vision Holdings, Inc. (NASDAQ: EYE)

NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Morris Kandinov Investigating FATE, HAFC, PEGA, and CVNA; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Fate Therapeutics, Inc., Hanmi Financial Corporation, Pegasystems Inc., and Carvana Co.... Full story

Yahoo Finance • 2 years ago

Why Shares of Fate Therapeutics Soared This Week

Shares of Fate Therapeutics (NASDAQ: FATE) were up by 23.7% for the week as of Friday afternoon, after being as high as 30.8% for the week, according to data provided by S&P Global Market Intelligence. The company focuses on cellular immun... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of PRTK, CIR, REUN, and FATE

NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRTK to Gurnet Point Capital a... Full story

Yahoo Finance • 2 years ago

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma FT576 BCMA-targeted CA... Full story

Yahoo Finance • 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripoten... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), and International Business Machines Corp. (NYSE: IBM)

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the... Full story

Yahoo Finance • 2 years ago

Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Hours to Actively Participate

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE)... Full story

Yahoo Finance • 2 years ago

FATE FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys, Mar. 22nd Deadline Pending in Securities Class Action

SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023 Lead Plaintiff... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class actio... Full story

Yahoo Finance • 2 years ago

DEADLINE ALERT for YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, March 20, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 2 years ago

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

LOS ANGELES, March 20, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased... Full story